Danaher (NYSE:DHR) Price Target Increased to $265.00 by Analysts at Stifel Nicolaus

Danaher (NYSE:DHR) had its price target boosted by equities researchers at Stifel Nicolaus from $250.00 to $265.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “hold” rating on the conglomerate’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 3.97% from the company’s current price.

DHR has been the topic of a number of other reports. Wells Fargo & Company started coverage on Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Bank of America increased their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Evercore ISI increased their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stephens assumed coverage on Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective on the stock. Finally, TD Cowen increased their target price on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $286.39.

Danaher Price Performance

Shares of DHR stock traded down $6.39 during trading hours on Wednesday, reaching $254.89. The company had a trading volume of 1,656,408 shares, compared to its average volume of 2,719,696. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a fifty day moving average of $270.67 and a 200-day moving average of $260.46. The company has a market capitalization of $188.79 billion, a price-to-earnings ratio of 43.20, a PEG ratio of 4.49 and a beta of 0.83. Danaher has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. On average, equities analysts anticipate that Danaher will post 7.59 earnings per share for the current year.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Company insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

A number of hedge funds have recently made changes to their positions in the company. Dakota Wealth Management increased its stake in shares of Danaher by 1.0% in the third quarter. Dakota Wealth Management now owns 8,161 shares of the conglomerate’s stock worth $2,269,000 after buying an additional 82 shares during the last quarter. Investment Research & Advisory Group Inc. increased its stake in shares of Danaher by 2.0% in the third quarter. Investment Research & Advisory Group Inc. now owns 5,161 shares of the conglomerate’s stock worth $1,435,000 after buying an additional 101 shares during the last quarter. DT Investment Partners LLC increased its stake in shares of Danaher by 7.4% in the third quarter. DT Investment Partners LLC now owns 1,041 shares of the conglomerate’s stock worth $289,000 after buying an additional 72 shares during the last quarter. Bogart Wealth LLC increased its stake in shares of Danaher by 1.3% in the third quarter. Bogart Wealth LLC now owns 33,765 shares of the conglomerate’s stock worth $9,387,000 after buying an additional 440 shares during the last quarter. Finally, Greystone Financial Group LLC increased its stake in shares of Danaher by 8.2% in the third quarter. Greystone Financial Group LLC now owns 34,367 shares of the conglomerate’s stock worth $9,555,000 after buying an additional 2,614 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.